Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Diabetes, Obesity and Metabolism

Volumn 6, Issue 4, 2004, Pages 280-285

  Durbin, R J ^a  

^a South Federal Family Practice   (United States)

Author keywords

Impaired glucose tolerance; Insulin resistance; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; KAPLAN MEIER METHOD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RISK REDUCTION; UNITED STATES;

EID: 3042685448     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.0348.x     Document Type: Article

References (23)

1. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 3G-10G.
2. Quinn L. Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. Nurs Clin North Am 2001; 36: 175-192.
3. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-29F.
4. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-3421.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
6. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2000.
7. Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2003; 52: 833-837.
8. Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes - lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 2003; 59: 165-180.
9. Turner NC, Clapham JC. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res 1998; 51: 33-94.
10. Ipp E, impaired glucose tolerance: the irrepressible alpha-cell? Diabetes Care 2000; 23: 569-570.
11. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312.
12. Sekino N, Kashiwabara A, Inoue T et al. Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia. Diabetes Obes Metab 2003; 5: 145-149.
13. Elasha H, Agrawal A, Jones NP, Bennett SMA, Walker M, Wilding J. Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance. Diabetologia 2001; 44 (Suppl. 1): A221.
14. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
15. Campbell IW. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000; 60: 1017-1028.
16. Gould E, Cobitz A. Long-term durability of rosiglitazone as monotherapy or in combination therapy in patients with type 2 diabetes. In: The Endocrine Society's 84th Annual Meeting; 2002 June 18-20. San Francisco, CA, 2002.
17. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
18. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
19. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
20. Sherwin RS, Anderson RM, Buse JB et al. The prevention or delay of type 2 diabetes. Diabetes Care 2003; 26 (Suppl. 1): S62-S69.
21. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-932.
22. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S33-S50.
23. Torn C. C-peptide and autoimmune markers in diabetes. Clin Lab 2003; 49: 1-10.